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Abstract
Background
The Vaxxas high-density microarray patch (HD-MAP) consists of a high density of micropro-
jections coated with vaccine for delivery into the skin. Microarray patches (MAPs) offer the
possibility of improved vaccine thermostability as well as the potential to be safer, more
acceptable, easier to use, and more cost-effective for the administration of vaccines than
injection by needle and syringe (N&S). Here, we report a phase I trial using the Vaxxas HD-
MAP to deliver a monovalent influenza vaccine that was to the best of our knowledge the
first clinical trial to evaluate the safety, tolerability, and immunogenicity of lower doses of
influenza vaccine delivered by MAPs.
Methods and findings
HD-MAPs were coated with a monovalent, split inactivated influenza virus vaccine contain-
ing A/Singapore/GP1908/2015 H1N1 haemagglutinin (HA). Between February 2018 and
March 2018, 60 healthy adults (age 18–35 years) in Melbourne, Australia were enrolled into
part A of the study and vaccinated with either: HD-MAPs delivering 15 μg of A/Singapore/
GP1908/2015 H1N1 HA antigen (A-Sing) to the volar forearm (FA); uncoated HD-MAPs;
intramuscular (IM) injection of commercially available quadrivalent influenza vaccine (QIV)
containing A/Singapore/GP1908/2015 H1N1 HA (15 μg/dose); or IM injection of H1N1 HA
antigen (15 μg/dose). After 22 days’ follow-up and assessment of the safety data, a further
150 healthy adults were enrolled and randomly assigned to 1 of 9 treatment groups.
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Participants (20 per group) were vaccinated with HD-MAPs delivering doses of 15, 10, 5,
2.5, or 0 μg of HA to the FA or 15 μg HA to the upper arm (UA), or IM injection of QIV. The
primary objectives of the study were safety and tolerability. Secondary objectives were to
assess the immunogenicity of the influenza vaccine delivered by HD-MAP. Primary and sec-
ondary objectives were assessed for up to 60 days post-vaccination. Clinical staff and par-
ticipants were blind as to which HD-MAP treatment was administered and to administration
of IM-QIV-15 or IM-A/Sing-15. All laboratory investigators were blind to treatment and partic-
ipant allocation. Two further groups in part B (5 participants per group), not included in the
main safety and immunological analysis, received HD-MAPs delivering 15 μg HA or
uncoated HD-MAPs applied to the forearm. Biopsies were taken on days 1 and 4 for analy-
sis of the cellular composition from the HD-MAP application sites.
The vaccine coated onto HD-MAPs was antigenically stable when stored at 40˚C for at
least 12 months. HD-MAP vaccination was safe and well tolerated; any systemic or local
adverse events (AEs) were mild or moderate. Observed systemic AEs were mostly head-
ache or myalgia, and local AEs were application-site reactions, usually erythema. HD-MAP
administration of 2.5 μg HA induced haemagglutination inhibition (HAI) and microneutralisa-
tion (MN) titres that were not significantly different to those induced by 15 μg HA injected IM
(IM-QIV-15). HD-MAP delivery resulted in enhanced humoral responses compared with IM
injection with higher HAI geometric mean titres (GMTs) at day 8 in the MAP-UA-15 (GMT
242.5, 95% CI 133.2–441.5), MAP-FA-15 (GMT 218.6, 95% CI 111.9–427.0), and MAP-FA-
10 (GMT 437.1, 95% CI 254.3–751.3) groups compared with IM-QIV-15 (GMT 82.8, 95% CI
42.4–161.8), p = 0.02, p = 0.04, p < 0.001 for MAP-UA-15, MAP-FA-15, and MAP-FA-10,
respectively. Higher titres were also observed at day 22 in the MAP-FA-10 (GMT 485.0,
95% CI 301.5–780.2, p = 0.001) and MAP-UA-15 (367.6, 95% CI 197.9–682.7, p = 0.02)
groups compared with the IM-QIV-15 group (GMT 139.3, 95% CI 79.3–244.5). Results from
a panel of exploratory immunoassays (antibody-dependent cellular cytotoxicity, CD4+ T-cell
cytokine production, memory B cell (MBC) activation, and recognition of non-vaccine
strains) indicated that, overall, Vaxxas HD-MAP delivery induced immune responses that
were similar to, or higher than, those induced by IM injection of QIV. The small group sizes
and use of a monovalent influenza vaccine were limitations of the study.
Conclusions
Influenza vaccine coated onto the HD-MAP was stable stored at temperatures up to 40˚C.
Vaccination using the HD-MAP was safe and well tolerated and resulted in immune
responses that were similar to or significantly enhanced compared with IM injection. Using
the HD-MAP, a 2.5 μg dose (1/6 of the standard dose) induced HAI and MN titres similar to
those induced by 15 μg HA injected IM.
Trial registration
Australian New Zealand Clinical Trials Registry (ANZCTR.org.au), trial ID 108
ACTRN12618000112268/U1111-1207-3550.
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Author summary
Why was this study done?
• Microarray patches (MAPs) offer several advantages over injection by needle and
syringe for administration of vaccines, including ease of use, greater acceptability, and
vaccine thermostability.
• Preclinical studies with several different vaccines have shown that MAPs can induce
comparable immune responses to injected vaccine but use less antigen (so-called ‘dose-
sparing’).
• However, the dose-sparing potential of MAPs has not yet been evaluated or demon-
strated in humans. This study was, to the best of our knowledge, the first clinical trial to
evaluate the immunogenicity of lower doses of vaccine delivered by MAPs.
What did the authors do and find?
• A randomised, partially blinded, placebo-controlled phase I clinical trial was conducted
using a MAP with a high density of microprojections (HD-MAP) to deliver an influenza
vaccine. Clinical staff and participants were blind as to which HD-MAP treatment was
administered. All laboratory investigators were blind to treatment and participant allo-
cation. The primary objectives of the trial were to assess safety and tolerability. The
immunogenicity of the MAP-delivered vaccine was assessed as a secondary objective,
using a number of different assays.
• Using the standard assay for assessing antibody responses to influenza vaccines (the
HAI assay), HD-MAP-delivered vaccine at one-sixth of the standard dose induced a
similar immune response to the full-dose of injected vaccine. When the full-dose was
delivered by HD-MAP, higher titres were seen and at earlier time-points compared with
the standard, injected influenza vaccine.
• Other immune parameters measured were at least as potent following HD-MAP deliv-
ery compared with the injected vaccine.
What do these findings mean?
• Our results suggest that influenza vaccine delivered by HD-MAP was safe and well toler-
ated, with evidence to suggest that dose-sparing and enhanced immune responses are
induced following HD-MAP delivery. The potential benefits of the technology suggest
that further research and development of HD-MAPs is warranted.
Introduction
Microarray patches (MAPs) are being developed by a number of parties as an alternative
method for vaccine delivery [1–7]. MAPs have several potential advantages compared with
injection by needle and syringe (N&S), including improved thermostability, ease of use and a
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reduced need for skilled healthcare workers for administration, greater acceptability by health-
care workers and recipients, avoidance of needle-stick injuries, and avoidance of the need for
reconstitution [8,9]. In addition, in preclinical studies with a range of vaccine types, MAPs
have been shown to enable dose-sparing, i.e., the induction of immune responses comparable
to those obtained with injected vaccines but with lower doses of antigen [10–17]. These results
are attributed to the targeted delivery of vaccine by MAPs to the dermis and epidermis of the
skin, both of which are rich in the antigen-presenting cells required to initiate immune
responses [10].
Clinical trials have been performed with several types of MAP including those with solid
microprojections such as the Nanopatch [2,19] and MAPs with dissolving microprojections
[3,7]. The Vaxxas high-density MAP (HD-MAP) differs from other MAPs in that it has a
high-density array of solid microprojections (thousands per cm2) formed from medical
grade polymer, and vaccine antigens are dispensed onto the tips of the projections and
dried. In the appropriate formulation, vaccines coated onto MAPs have improved thermo-
stability compared with the standard liquid formulation [18]. Initial clinical trials found the
original Nanopatch to be safe, well tolerated, preferred by recipients to N&S, and able to
induce immune responses at least as potent as intramuscular (IM) injection [2,19]. The
Nanopatch MAPs used in these initial clinical trials were formed from dry-etched mono-
crystalline silicon and also had a high density of microprojections. However, HD-MAPs as
used in this study, are prefabricated by injection-moulding of polymer, which means that
large-scale commercial manufacture will be less expensive and able to meet seasonal influ-
enza product release timelines.
In this report, we describe the first clinical trial to evaluate the safety and tolerability of Vax-
xas HD-MAPs fabricated from polymer; this is also, to the best of our knowledge, the first clin-
ical trial with any MAP to evaluate the immunogenicity of doses lower than the standard IM
dose delivered by MAP. We used a monovalent influenza vaccine as a model antigen to assess
the safety and tolerability of HD-MAPs as primary objectives of the study. In addition, serolog-
ical and cell-mediated immune responses induced by HD-MAP delivery, compared with IM
injection, were analysed as a secondary objective.
Methods
Trial participants and study design
The study was approved by the Bellberry Human Research Ethics Committee (Adelaide,Aus-
tralia) and conducted in accordance with the Australian National Health and Medical
Research Council’s National Statement of Ethical Conduct in Human Research (2007; incor-
porating all updates as at May 2015). Written informed consent was obtained from all partici-
pants. The trial was registered with Australian New Zealand Clinical Trials Registry
(ANZCTR.org.au), trial ID ACTRN12618000112268/U1111-1207-3550. This study is reported
as per the Consolidated Standards of Reporting Trials (CONSORT) guidelines (S1 Checklist).
The study was a two-part, randomised, partially double-blind, placebo-controlled trial con-
ducted at Nucleus Network Pty Ltd (Melbourne, Australia). Clinical staff and participants
were blind as to which MAP treatment was administered and to administration of IM-QIV-15
or IM-A/Sin-15. All laboratory investigators were blind to treatment and participant alloca-
tion. The primary objective was to measure the safety and tolerability of A/Singapore/GP1908/
2015 H1N1 (A/Sing) monovalent vaccine delivered by HD- MAP in comparison to an
uncoated HD-MAP and IM injection of a quadrivalent seasonal influenza vaccine (QIV) deliv-
ering approximately the same dose of A/Sing HA protein. Exploratory outcomes were to evalu-
ate the immune responses to HD-MAP application to the forearm with A/Sing at 4 dose levels
A phase I clinical trial evaluating influenza vaccination using a HD-MAP
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in comparison to IM administration of A/Sing at the standard 15 μg HA per dose per strain
and to assess further measures of immune response through additional assays and assessment
of the local skin response via punch biopsy of the HD-MAP application sites.
Because the primary objective was to assess safety and tolerability, the sample size was not
based on any formal statistical calculations; this is typical of phase I vaccination studies. How-
ever, for this study, the 20 participants in a group would have an 80% probability of showing at
least one adverse event if the true rate of that event is more than 8%, and, over the 160 partici-
pants receiving any MAP, there was an 80% probability of showing at least one adverse event if
the true rate of that event is more than 1%. Randomisation was predetermined, and sealed par-
ticipant-specific code break envelopes were produced by the statistician responsible for prepar-
ing the randomisation.
Part A of the trial was a ‘lead-in’ phase to indicate whether the safety, tolerability, and
immunogenicity results seen with the HD-MAP were consistent with the results obtained pre-
viously with the silicon Nanopatch [2] before expanding into the larger study (part B).
Healthy males and females (nonpregnant and non-nursing) aged 18 to 50 years with a BMI
in the range of 18 to 30 kg/m2 (N = 60) were recruited from the panel of volunteers at Nucleus
Network, screened, and randomly allocated into 1 of 4 vaccination groups for part A of the
trial. Participants (N = 150) were randomly allocated into 1 of 9 vaccination groups for part B
(Fig 1). Participants were not screened or selected for on the basis of anti-H1N1 HAI titre. The
demographic profile of the participants is provided in Table 1.
The 4 treatment groups in part A were 15 μg HA per dose administered by HD-MAP
applied to the volar surface of the forearm (A-MAP-FA-15), QIV (15 μg A/Sing HA per dose)
injected IM into the deltoid muscle (A-IM-QIV-15), uncoated HD-MAPs applied to the volar
surface of the forearm (A-MAP-FA-0), and monovalent purified harvest (MPH) containing
15 μg A/Sing HA injected IM (A-IM-A/Sin-15). The treatment groups for part B were
HD-MAPs applied to the volar surface of the forearm delivering 15 (MAP-FA-15), 10
(MAP-FA-10), 5 (MAP-FA-5), or 2.5 μg HA (MAP-FA-2.5), uncoated HD-MAPs applied to
the volar forearm (MAP-FA-0), HD-MAPs delivering 15 μg HA applied to the upper arm over
the deltoid muscle (MAP-UA-15), and QIV (15 μg A/Sing HA per dose) injected IM
(IM-QIV-15).
Two further groups (5 participants per group) were included in part B. These participants
provided additional informed consent during screening and received HD-MAPs delivering
15 μg (MAP-FA-15-bio) or uncoated HD-MAPs (MAP-FA-0-bio) applied to the forearm.
Biopsies were taken on days 1 and 4 for analysis of the cellular composition from the
HD-MAP application sites. Results of these analyses will be presented elsewhere. These 10 par-
ticipants were not included in the main safety and immunological analysis.
Vaccines
Split influenza A/Sing MPH was supplied by Seqirus Pty Ltd (Australia). Sulfobutyl ether (β)
cyclodextrin (SBECD) (Ligand, San Diego, CA) was added at a ratio of 4 to 1 (% w/w) HA pro-
tein to preserve antigen potency during coating and storage.
Influenza vaccines Afluria Quadrivalent 2017–2018 (lot XF 33608 expiry 30 June 2018) and
Afluria Quad 2018 (lot 49601–00901 expiry February 2019) (Seqirus Pty Ltd) were used as IM
controls in parts A and B of the trial, respectively. They contained A/Singapore/GP1908/2015
(A/Michigan/45/2015 [H1N1-like]); A/Hong Kong/4801/2014 (NYMC X-263B) (Afluria
Quadrivalent 2017–2108) or A/Singapore/INFIMH-16-0019/2016 [H3N2-like] (Afluria Quad
2018); B/Phuket/3073/2013; and B/Brisbane/46/2015 [B/Brisbane/60/2008-like], all at a nomi-
nal 15 μg HA/dose.
A phase I clinical trial evaluating influenza vaccination using a HD-MAP
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Fig 1. Trial profile. Randomisation and flow of participants in parts A and B of the study. Participants in part A were vaccinated with either A/Singapore/
GP1908/2015 H1N1 delivered by HD-MAP (A-MAP-FA-15), IM injection of Afluria quadrivalent vaccine (A-IM-QIV-15), uncoated HD-MAP
(A-MAP-FA-0), or A/Singapore/GP1908/2015 H1N1 monovalent pooled harvest injected IM (IM-SIN-15). Participants in part B were vaccinated with A/
Singapore/GP1908/2015 H1N1 at 15, 10, 5, or 2.5 μg HA/dose delivered by HD-MAPs applied to the volar forearm (MAP-FA-15, MAP-FA-10, MAP-FA-
5, MAP-FA-2.5), uncoated HD-MAPs (MAP-FA-0), A/Singapore/GP1908/2015 H1N1 at 15 μg HA/dose delivered by HD-MAP applied to the upper arm
(MAP-UA-15), or injected IM with Afluria quadrivalent vaccine (IM-QIV-15). HA, haemagglutinin; HD-MAP, high-density microarray patch; IM,
intramuscular.
https://doi.org/10.1371/journal.pmed.1003024.g001
Table 1. Participant demographics.
PART A A-MAP-FA-
15
A-IM-QIV-
15
A-MAP-FA-
0
A-IM-A/Sin-
15
Number 15 15 15 15
Age, mean (SD) 26.7 (8.0) 26.9 (7.1) 26.9 (6.6) 25.3 (6.8)
Age, range (years) 18–44 20–42 19–42 18–38
Female, number (%) 12 (80) 10 (67) 10 (67) 10 (67)
Male, number (%) 3 (20) 5 (33) 5 (33) 3(33)
BMI (kg/m2), mean (SD) 22.8 (2.9) 24.1 (2.4) 23.9 (3.9) 23.1 (3.0)
Race, number (%)
Asian 1 (7) 1 (7) 4 (27) 6 (40)
Black or African American 1 (7) 0 (0) 0 (0) 1 (7)
White 13 (87) 13 (87) 10 (67) 8 (53)
White, American Indian, or
Alaskan Native
0 (0) 0 (0) 1 (7) 0 (0)
White, Asian 0 (0) 1 (7) 0 (0) 0 (0)
PART B MAP-FA-15 MAP-FA-10 MAP-FA-5 MAP-FA-2.5 MAP-FA-
0
MAP-UA-
15
IM-QIV-
15
MAP-FA-
15-bio
MAP-FA-
0-bio
Number 20 20 20 20 20 20 20 5 5
Age, mean (SD) 27.4 (7.4) 26.1 (6.1) 26.5 (6.7) 24.7 (5.4) 26.2 (7.1) 27.4 (9.6) 24.2 (3.4) 39.6 (8.1) 29.6 (4.9)
Age, range (years) 18–43 18–40 19–45 18–36 18–43 19–48 19–32 31–50 24–37
Female, number (%) 13 (65) 16 (80) 11 (55) 14 (70) 13 (65) 11 (55) 14 (70) 4 (80) 3 (60)
Male, number (%) 7 (35) 4 (20) 9 (45) 6 (30) 7 (35) 9 (45) 6 (30) 1 (20) 2 (40)
BMI (kg/m2), mean (SD) 24.1 (2.6) 23.0 (3.4) 23.2 (3.5) 22.8 (2.5) 23.0 (3.0) 24.0 (3.1) 23.4 (3.1) 22.7 (2.6) 23.7 (2.1)
Race, number (%)
Asian 3 (15) 7 (35) 8 (40) 5 (25) 5 (25) 4 (20) 6 (30) 0 (0) 0 (0)
Asian, Aboriginal/Torres
Strait Islander
0 (0) 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Asian, Native Hawaiian or
Pacific Islander
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
Black or African American 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
Other mixed race 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 1 (5) 0 (0) 0 (0)
White 17 (85) 11 (55) 12 (60) 14 (70) 15 (75) 10 (50) 13 (65) 5 (100) 5 (100)
White, Aboriginal/Torres
Strait Islander
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
White, Asian 0 (0) 1 (5) 0 (0) 1 (5) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
White, Black or African
American, Asian
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
Abbreviations: A/Sing, A/Singapore/GP1908/2015 H1N1; bio, biopsy; BMI, body mass index; FA, forearm; IM, intramuscular; MAP, microarray patch; QIV,
quadrivalent influenza vaccine; UA, upper arm
https://doi.org/10.1371/journal.pmed.1003024.t001
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HD-MAP manufacture
HD-MAPs were manufactured by injection moulding of a polymer to produce HD-MAPs of
10 × 10 mm with approximately 3,136 projections per patch. Each projection was approxi-
mately 250 μm high, 120 μm wide at the base, and had a sharp point of< 25 μm. Vaccine was
aseptically applied to the tips of gamma-irradiated (�25 kGy; Steritech, Australia) HD-MAPs
using a ‘Direct-jet’ process (Vaxxas Pty Ltd, Australia) that deposits individual droplets onto
the tip of each projection.
HD-MAPs were produced to deliver 2 different doses of A/Sing, 2.5 μg and 5.0 μg (referred
to as 2.5 μg and 5 μg HD-MAPs), as well as uncoated (placebo) HD-MAPs. The doses cited
throughout this report refer to the estimated delivered dose. Preparatory studies using ex vivo
and in vivo pig-skin assays determined the delivery efficiency of this MAP-vaccine combina-
tion to be approximately 50%; therefore, to deliver a 2.5 μg dose, 5 μg MPH was loaded onto
each MAP. Following coating, HD-MAPs were placed into aluminium MediCan containers
(Amcor, UK), foil-sealed, and stored at 2 to 8˚C with desiccant until use. The antigen-coated
HD-MAPs were used within 6 months of manufacture.
Vaccination procedure
All HD-MAP participants in part A and part B had 3 HD-MAPs applied. Doses of 15, 10, and
5 μg HA per participant were achieved by applying three, two, or one 5 μg HD-MAPs plus 0, 1,
or 2 uncoated HD-MAPs. Participants in the 2.5-μg HA group received a single 2.5-μg
HD-MAP and 2 uncoated HD-MAPs. Although this approach means that the area of exposure
to antigen varied, it had several advantages. This strategy simplified the manufacturing and
product release procedures, because only 3 types of HD-MAP (5 μg, 2.5 μg, and uncoated)
were required. It also greatly improved the precision of the 5, 10, and 15 μg doses and enabled
within-participant comparison of the local skin response of antigen-loaded compared with
uncoated HD-MAPs.
Participants were vaccinated on day 1, with HD-MAPs applied to the nondominant arm
(where possible). Application sites were selected to be free from scarring, tattoos, skin condi-
tions, sunburn, and heavy hair. The application process used was the same as described previ-
ously [2].The area for application was marked, swabbed using a 70% ethanol swab, and
photographed. HD-MAPs were applied using a separate spring-powered applicator that gener-
ated an application speed of 20 m/s and left on the skin for 2 min before being removed. All
applications were performed by trained study team members.
Participants were monitored by clinic safety assessment visits at days 1, 2 (part B only), 4, 8,
22, and 61 and phone calls at days 2 (part A only), 3, 36, and 50. On day 1, all vaccination sites
were assessed at prevaccination, 10 min, 1 h, and 2 h after HD-MAP or IM administration.
Photographs of the treatment sites were taken at every clinic review. Skin reactions were
assessed for erythema and oedema, with scores combined to generate a skin irritation index
(SII) as described previously [2,19]. Induration, tenderness, bruising, skin flaking, visibility,
itching, and bleeding were also assessed. Pain scores were collected at 1 and 10 min, 1 and 2 h
after the patch removal, and on subsequent visits, using a visual analogue scale with 0 = no
pain; 5 = moderate pain; 10 = worst pain possible.
Serology assays
Haemagglutination inhibition (HAI) assays were run on blinded serum samples collected on
days 1, (prevaccination), 4, 8, 22, and 61 (360biolabs Pty Ltd, Australia). Samples were treated
with receptor destroying enzyme (Denka Seiken Co Ltd, Japan) and adsorbed to washed,
packed turkey red blood cells (TRBCs) (for 60 min at room temperature (RT). TRBCs were
A phase I clinical trial evaluating influenza vaccination using a HD-MAP
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diluted to 1% v/v in PBS prior to testing. Two-fold serum dilutions starting from 1:5 were pre-
pared, and 4 HA Units/25 μL of A/Singapore/GP1908/2015 virus (WHO Collaborating Centre,
Australia) were added to each test well and incubated for 60 min at RT. TRBCs (25 μl, 0.5% v/
v) were added and incubated for a further 60 min at RT. The HAI titre was the reciprocal of
the highest dilution of the sera that completely inhibited agglutination of TRBC by the virus.
Microneutralisation (MN) assays (360biolabs Pty Ltd) were conducted on serum samples
collected on days 1 and 22 as described by Wagner and colleagues [20], with the exception that
0.5% bovine serum albumin was used instead of 1% bovine serum albumin in the virus diluent.
Briefly, samples were heat inactivated at 56˚C for 30 min. Two-fold serum dilutions starting
from 1:20 were prepared and 100 TCID50 of A/Singapore/GP1908/2009 virus (WHO Collabo-
rating Centre, Australia) were added to each test. Prevention of infection of MDCK cells by
the virus was tested using enzyme-linked immunosorbent assay (ELISA) detection of influenza
nucleoprotein.
Antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) were
assayed using an ELISA that detected the ability of immobilized A/Sing MPH-specific antibod-
ies to cross-link soluble recombinant FcγRIIIA receptor dimers [21]. The assays were con-
ducted at the Department of Microbiology and Immunology, University of Melbourne,
Australia. Serum samples collected on days 1 and 22 from participants in groups MAP-FA-0,
MAP-FA-15, MAP-UA-15, and IM-QIV-15 were tested. Briefly, 96-well Nunc Maxisorp plates
(Thermofisher Scientific, Waltham, MA) were coated for 16 h at 4˚C with 50 ng of A/Singa-
pore/GP1908/2015 HA in PBS, washed with PBS + 0.05% Tween20 (PBST), and blocked with
SuperBlock (Thermofisher Scientific) before addition of duplicate serially diluted serum sam-
ples (1:20–1:43,740). Plates were incubated at 37˚C for 1 h then washed using PBST. An
FcγRIIIA Val158 ectodomain biotin dimer (0.1 μg/mL) was added and incubated at 37˚C for 1
h then washed using PBST. Antibody-FcγRIIIA complexes were detected using a 1:10,000 dilu-
tion of streptavidin-HRP (Thermofisher Scientific) and development with 3,3’,5,5’-tetra-
methylbenzidine substrate (Sigma-Aldrich, St. Louis, MO). The reaction was stopped with
0.16M H2SO4, and absorbance was measured at 450 nm. Serum concentrations giving half-
maximal signal (EC50) were determined using a fitted curve (4 parameter log regression) and
GraphPad Prism (GraphPad Software, San Diego, CA, www.graphpad.com).
Salivary IgA
Saliva samples were collected from participants in the MAP-FA-0, MAP-FA-15, MAP-UA-15,
and IM-QIV-15 groups on days 1, 4, 8, and 22. Participants chewed on the cotton swab of a
Salivette saliva collector (Sarstedt, France) for approximately 1 min. Following centrifugation,
the supernatant (saliva) was stored at −80˚C. Influenza specific immunoglobulin A (IgA) was
detected by ELISA; assays were carried out at Vaxxas Pty Ltd. Specifically, saliva samples seri-
ally diluted in 4 mg/mL BSA in PBS (PBSA) were added to Nunc Maxisorp plates (Thermo-
fisher Scientific) previously coated overnight with A/Singapore/GP1908/2015 HA MPH (60 μl
per well at 2 μg/ml) and blocked with PBSA. The presence of A/Sing HA specific IgA was
detected using HRP-conjugated goat anti-human polyclonal IgA (PA1-74395, Thermofisher
Scientific) and ABTS substrate (Sera-Care, Milford, MA). The reaction was stopped with 1%
SDS, and absorbance was measured at 405 nm.
MBCs
Peripheral blood mononuclear cells (PBMCs) were collected and cryopreserved from partici-
pants in the MAP-FA-0, MAP-FA-15, MAP-UA-15, and IM-QIV-15 groups on days 1 and 22
and stored in liquid nitrogen until use. Assays were carried out at the Department of
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Microbiology and Immunology, University of Melbourne. Recombinant HA proteins for use
as flow cytometry probes for A/Michigan/45/2015, A/New Caledonia/20/1999, and the stabi-
lised H1N1 stem domain were derived as previously reported [22]. HA-specific B cells were
identified within cryopreserved human PBMC by co-staining with HA probes conjugated to
SA-PE, SA-APC, or SA-Ax488 (Thermofisher Scientific). Monoclonal antibodies for surface
staining included CD19-ECD (J3-119) (Beckman Coulter, Indianapolis, IN), IgM-BUV395
(G20-127), CD21-BUV737 (B-ly4), IgD-Cy7PE (IA6-2), IgG-BV786 (G18-145) (BD Biosci-
ences, USA), CD14-BV510 (M5E2), CD3-BV510 (OKT3), CD8a-BV510 (RPA-T8),
CD16-BV510 (3G8), CD10-BV510 (HI10a), CD27-BV605 (O323) (Biolegend, San Diego, CA),
and IgA-Vio450 (REA1014) (Miltenyi, Auburn, CA). Background B cells interacting with
streptavidin were excluded by staining with SA-BV510 (BD Biosciences, San Jose, CA). Cell
viability was assessed using Aqua Live/Dead amine-reactive dye (Thermofisher Scientific).
Samples were collected using a BD Fortessa configured to detect 18 fluorochromes, and analy-
sis was performed using FlowJo software version 9.5.2 (Becton Dickinson, Ashland, OR).
Flow cytometry of T cells
Cytokine production by CD4+ and CD8+ T cells was assessed using a modification of the
method described by Landry and colleagues [23]. Assays were carried out at the University of
Queensland Diamantina Institute, Faculty of Medicine, Australia. PBMC were thawed, plated
out at 1.5 × 106 per well, and rested for 6 h. After washing, the PBMC were stimulated with
either A/Sing MPH for 20 h (20 μg/ml) or for 6 h with a pool of overlapping synthetic peptides
(17 amino acids long overlapping by 11 amino acids, 5 μg/ml) spanning the A/Sing HA
sequence (Mimotopes Pty Ltd, Australia). Media only and PMA/ionomycin were used as nega-
tive and positive controls, respectively. Golgi blockers (monensin and brefeldin A) were added
5 h before the end of incubation. Cells were labelled with surface stains Live/Dead Aqua (for
viability), anti-CD3 BV785, anti-CD4 FITC, and anti CD8 APC/Cy7 (all from Biolegend), and
then fixed, permeabilised, and labelled with anti-interferon (IFN)-γ Ax647, anti-tumour
necrosis factor (TNF)-α BV421, and anti-interleukin (IL)-2 PE (all from Biolegend). Samples
were analysed on a Becton Dickinson LSR Fortessa X20 within 24 h of the last wash step.
Approximately 500,000 events were acquired, and the raw data were analysed initially using
FlowJo (to obtain percentage positive values for each cytokine) before using SPICE (http://
exon.niaid.nih.gov/spice) software to analyse background-subtracted values.
Thermostability
A/Sing-coated HD-MAPs were stored at 2 to 8˚C, 25˚C ± 2˚C/60% ± 5% relative humidity
(RH) and 40˚C ± 2˚C/60% ± 5% RH for 12 months. At the designated timepoints, the coating
was eluted from the HD-MAPs in 1 mL elution buffer (0.041% w/w Hypromellose (Shin-Etsu
Chemical Co Ltd, Japan), 0.0295% w/w trehalose dihydrate (Sigma Aldrich Corp., St. Louis,
MO)) using water bath sonication at 20 to 28˚C, and the potency of HA was determined by
enzyme immunoassay [24].
Statistical analysis
The increases in HAI titres and MN titres were compared between groups using both paramet-
ric (Student t test) and nonparametric (exact Mann-Witney test) methods. The significance
level was assumed to be p< 0.05 (two tailed). Results from the parametric analysis are pre-
sented in the main text, tables, and figures. Results from the nonparametric analyses of HAI
and MN titres are included in S1 Table and S2 Table. The proportions of participants seropro-
tected or seroconverted were compared between groups using a Pearson’s chi-square test with
A phase I clinical trial evaluating influenza vaccination using a HD-MAP
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continuity correction (SAS version 9.4, SAS Institute Inc., Cary, NC). As this was an early
phase study, no adjustments were made for multiplicity for any of the analyses, including
immunogenicity assays. For the ADCC and MBC response assays, all groups were compared
using Kruskal Wallis nonparametric tests (with no corrections for multiple comparisons) and
Dunn’s multiple comparison post-tests. Within-group comparisons of cytokine production by
CD4+ cells at day 1 and day 22 were made using the Wilcoxon rank sum test (GraphPad
Software).
Results
Stability of A/Sing HA on HD-MAPs at elevated temperatures
To obtain stability data ahead of the clinical product manufacture, a GLP stability study was
performed testing a 5 μg and 15 μg HA A/Sing loading on HD-MAPs. This loading range was
selected to bracket the range of A/Sing HA loadings intended for use in the clinic. The A/Sing
HA antigen coated at 5 μg or 15 μg per HD-MAP was stable when stored at 2 to 8˚C, 25˚C, or
40˚C for at least 12 months (Fig 2).
Participants and study procedures
Between 23 Feb 2018 and 23 March 2018, 60 participants (out of 370 screened) were enrolled
into part A of the study and vaccinated as described above (Fig 1). The safety data and HAI
responses from part A participants at days 1 and 22 (S1 Fig) were assessed by a panel of experts
and judged to be acceptable and consistent with results obtained in the previous study with sil-
icon Nanopatches [2], and the study proceeded to part B. For part B, 150 participants were
enrolled between 20 April 2018 and 26 June 2018, randomly assigned to 1 of 9 treatment
groups and vaccinated as described above (Fig 1).
Summary of adverse events
For both part A and part B of the study there were no deaths, serious adverse events (SAEs),
adverse events (AEs) with a severe intensity, or participant withdrawals due to AEs. No clini-
cally significant events were observed with respect to clinical laboratory tests, vital signs, or
oral temperature.
Fig 2. Coating and stability of A/Sing HA on HD-MAPs. The left-hand panel shows a scanning electron micrograph of HD-MAPs coated with A/Sing MPH. The
coated vaccine is visible on the tips and top half of the projections. The graphs show stability of A/Sing HA on HD-MAPs coated with either 5 μg or 15 μg HA (in A/
Sing MPH) indicated by the dotted line. Antigen-coated HD-MAPs were stored at 2 to 8˚C, 25˚C or 40˚C at 60% ± 5% RH for 1, 3, 6, or 12 months. At each time
point, antigen was eluted from the HD-MAP and the HA content determined by enzyme immunoassay. A/Sing, A/Singapore/GP1908/2015 H1N1; HA,
haemagglutinin; HD-MAP, high-density microarray patch; RH, relative humidity.
https://doi.org/10.1371/journal.pmed.1003024.g002
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A total of 60 treatment emergent adverse events (TEAEs) were reported for part A in 37
participants (62%; Table 2). Of these, 31 events in 20 participants (33%) were considered possi-
bly, probably, or definitely related to study treatment. Two of the treatment-related (TR)-
TEAEs were of moderate severity. Both were headaches, one in the A-MAP-FA-0 group and
one in the A-IM-QIV-15 group.
In Part B nonbiopsy groups, a total of 235 TEAEs were reported in 111 participants (79%).
Of these, 158 were considered related to study treatment; 6 were of moderate severity, and the
remainder were mild. There were 3 moderate TR-TEAEs in the MAP-FA-2.5 group: headache,
myalgia, and application site pruritis. There was 1 moderate event (headache) in the MAP-FA-
5 group and 2 moderate events (headache and cervical lymphadenopathy) in the MAP-FA-10
group (Table 2). Of the 158 TR-TEAEs, 149 were related to the local skin response of the
HD-MAP or IM injection. A total of 14 TEAEs were reported in the 2 biopsy groups with 8
considered related to study treatment. All these TR-TEAEs were of mild severity.
Resolution of skin responses at the HD-MAP application site
A summary of application and injection site TEAEs is presented in Table 3. No cases of surface
bleeding were noted in any of the 480 patch applications performed across the study. The fre-
quency of local skin reactions was higher with A/Sing-coated HD-MAPs compared with
uncoated HD-MAPs, but there was no apparent difference in skin responses at the 2 delivered
dose variants of A/Sing-coated HD-MAP. There was a low incidence of tenderness and indu-
ration around the application site, with higher prevalence in the A/Sing HD-MAP groups.
Itching scores were low and most frequent at day 4 with more itching reported for the A/Sing-
coated HD-MAP applications than uncoated. One participant reported a moderate AE (itch-
ing) on day 1 for all 3 application sites (1 × 2.5 μg HD-MAP, 2 × uncoated HD-MAP) from 10
min to 1 h after application. Any skin flaking that was observed at the HD-MAP application
Table 2. TEAEs.
Number (%) participants with TEAEs
PART A MAP-FA-15
(N = 15)
IM-QIV-15
(N = 14)
MAP-FA-0
(N = 15)
IM-A/Sing-15
(N = 15)
Total
TEAEs 10 (67) 13 (87) 9 (60) 5 (33) 37 (62)
TR-TEAEs 6 (40) 8 (53) 3 (20) 3 (20) 20 (33)
Mild TR-TEAEs 6 (40) 7 (50) 2 (13) 3 (20) 18 (31)
Moderate
TR-TEAEs
0 (0) 1 (7) 1 (7) 0 (0) 2 (3)
Severe
TR-TEAEs
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PART B MAP-FA-15
(N = 20)
MAP-FA-10
(N = 20)
MAP-FA-5
(N = 20)
MAP-FA-2.5
(N = 20)
MAP-FA-0
(N = 20)
MAP-UA-15
(N = 20)
IM-QIV-15
(N = 20)
Total
TEAEs 18 (90) 18 (90) 18 (90) 18 (90) 12 (60) 18 (90) 9 (45) 111
(79)
TR-TEAEs 18 (90) 17 (85) 16 (80) 15 (75) 3 (15) 18 (90) 2 (10) 89 (64)
Mild TR-TEAEs 18 (90) 15 (75) 15 (75) 12 (60) 3 (15) 18 (90) 2 (10) 83 (69)
Moderate
TR-TEAEs
0 (0) 2 (10) 1 (5) 3 (15) 0 (0) 0 (0) 0 (0) 6 (4)
Severe
TR-TEAEs
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Number and severity of TR-AEs by treatment group for parts A and B, excluding biopsy groups.
Abbreviations: A/Sing, A/Singapore/GP1908/2015 H1N1; FA, forearm; IM, intramuscular; MAP, microarray patch; QIV, quadrivalent influenza vaccine; TEAE,
treatment emergent adverse event; TR-AE, treatment-related adverse event; TR-TEAE, treatment related treatment emergent adverse event; UA, upper arm
https://doi.org/10.1371/journal.pmed.1003024.t002
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sites peaked at day 8 and was similar between the active HD-MAP dose variants and the FA
and UA sites, with the uncoated HD-MAPs exhibiting less skin flaking.
A typical example of application site reaction and resolution following application of two
5 μg and one uncoated HD-MAP to the forearm of a single participant is shown in Fig 3. The
initial skin response over 2 h was similar between the active and uncoated HD-MAPs, with a
defined erythema and occasional petechiae and oedema directly under all application sites. At
days 4 and 8, there was less erythema at the uncoated HD-MAP application site compared
with the active HD-MAP sites. At day 22, reactions to the uncoated HD-MAP were undetect-
able but were still just detectable in this participant at the active HD-MAP application site.
Table 3. Application and injection site TEAEs.
Number (%) participants with local TEAEs
PART A MAP-FA-15
(N = 15)
IM-QIV-15
(N = 14)
MAP-FA-0
(N = 15)
IM-A/Sing-15
(N = 15)
Total
Application site
visibility
4 (27) 0 (0) 2 (13) 0 (0) 6 (10)
Application site
erythema
3 (20) 0 (0) 3 (20) 0 (0) 6 (10)
Application site
exfoliation
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Application site
oedema
2 (13) 0 (0) 0 (0) 0 (0) 2 (3)
Application site
pruritis
1 (7) 0 (0) 1 (7) 0 (0) 2 (3)
Application site
reaction
1 (7) 0 (0) 0 (0) 0 (0) 1 (2)
Injection site
discomfort
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Injection site pain 0 (0) 0 (0) 0 (0) 2 (13) 2 (3)
Injection site pruritis 0 (0) 0 (0) 0 (0) 1 (7) 1 (2)
PART B MAP-FA-15
(N = 20)
MAP-FA-10
(N = 20)
MAP-FA-5
(N = 20)
MAP-FA-2.5
(N = 20)
MAP-FA-0
(N = 20)
MAP-UA-15
(N = 20)
IM-QIV-15
(N = 20)
Total
Application site
visibility
10 (50) 12 (60) 10 (50) 10 (50) 1 (5) 7 (35) 0 (0) 50
(36)
Application site
erythema
10 (50) 7 (35) 9 (45) 7 (35) 0 (0) 9 (45) 0 (0) 42
(30)
Application site
exfoliation
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 1 (1)
Application site
oedema
1 (5) 0 (0) 1 (5) 3 (15) 0 (0) 1 (5) 0 (0) 6 (4)
Application site
pruritis
0 (0) 0 (0) 1 (5) 1 (5)� 0 (0) 1 (5) 1 (5) 4 (3)
Application site
reaction
4 (20) 6 (30) 3 (15) 4 (20) 0 (0) 5 (25) 0 (0) 22
(16)
Injection site
discomfort
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 1 (1)
Injection site pain 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 1 (1)
Injection site pruritis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Number and severity of application and injection site TEAEs at all time points by treatment group for parts A and B, excluding biopsy groups. All events were mild, with
the exception of �, which indicates a moderate event.
Abbreviations: A-Sing, A/Singapore/GP1908/2015 H1N1; FA, forearm; IM, intramuscular; MAP, microarray patch; QIV, quadrivalent influenza vaccine; TEAE,
treatment emergent adverse event; UA, upper arm
https://doi.org/10.1371/journal.pmed.1003024.t003
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Fig 3. Representative images of skin reactions over time at HD-MAP application sites (single participant (S316/B0139), MAP-FA-10 group). Photographs show 3
HD-MAPs applied to adjacent sites on the forearm; site 1 (nearest the elbow crease) is the uncoated patch, and sites 2 and 3 are applications of the A/Sing coated
HD-MAPs delivering 5 μg HA into the skin per patch. Timepoints at 1 h and 24 h are not shown in the image sequence. Photo credit Nucleus Network Pty Ltd. A/Sing, A/
Singapore/GP1908/2015 H1N1; FA, forearm; HA, haemagglutinin; HD-MAP, high-density microarray patch; MAP, microarray patch.
https://doi.org/10.1371/journal.pmed.1003024.g003
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Average erythema scores for all 3 HD-MAP variants (5, 2.5, and 0 μg HA) were similar over
the first 2 h of response, but erythema following A/Sing coated HD-MAP application peaked
between 24 and 72 h for both the FA and UA sites, before resolving significantly by day 8. The
peak in erythema was reflected by the SII scores (erythema and oedema scores combined),
which followed the same trend (Fig 4A). Approximately half of the active A/Sing coated
HD-MAP application sites remained slightly visible at day 61, whereas only 2 participants
showed any visual evidence of application with an uncoated HD-MAP at this time point (Fig
4B).
Self-reported pain scores after HD-MAP application or IM injection were very low overall
(Fig 5). The highest scores for pain were experienced at the 1-min post-treatment application
assessment (i.e., prior to HD-MAP removal).
Serum antibody responses following vaccination
The geometric mean titres (GMTs) of HAI antibodies at days 1, 4, 8, 22, and 61 for participants
in part B are shown in Fig 6. There was no increase in HAI titre in participants receiving
uncoated HD-MAPs. In participants receiving the vaccine, either by HD-MAP or IM, titres
did not increase above baseline at day 4, but at day 8 the GMTs were significantly higher in the
MAP-FA-10 (GMT 437.1, 95% CI 254.3–751.3 p< 0.001), MAP-UA-15 (GMT 242.5, 95% CI
Fig 4. Time course of injection site reaction resolution. (A) SII, scale 0 to 8. (B) visibility (i.e., colouration at the
application site), scale 0 to 3. Symbols represent mean scores ± 95% confidence intervals. Day, study day (HD-MAP
applied on day 1); HD-MAP, high-density microarray patch; Min, minutes after HD-MAP application; SII, skin
irritation index.
https://doi.org/10.1371/journal.pmed.1003024.g004
Fig 5. Self-reported pain scores using a visual analogue scale from 0 (no pain) to 10 (worst pain imaginable).
Symbols represent mean scores ± 95% confidence intervals. Day, study day (HD-MAP applied on day 1); HD-MAP,
high-density microarray patch; Min, minutes after HD-MAP application.
https://doi.org/10.1371/journal.pmed.1003024.g005
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133.2–441.5, p = 0.02), and MAP-FA-15 (GMT 218.6, 95% CI 111.9–427.0, p = 0.04) compared
with the IM-QIV-15 group (GMT 82.8, 95% CI 42.4–161.8). Titres continued to increase in all
active groups until day 22 and remained significantly higher in the MAP-FA-10 (GMT 485.0
95% CI 301.5–780.2, p = 0.001) and MAP-UA-15 groups (GMT 367.6, 95% CI 197.9–682.7, p
= 0.02) compared with the IM-QIV-15 group (GMT 139.3, 95% CI 79.3–244.5). HAI GMTs
were also significantly higher at day 61 in the MAP-FA-10 (GMT 309.1, 95% CI 199.1–479.9 p
= 0.01) and MAP-UA-15 (GMT 278.6, 95% CI 152.7–508.1, p = 0.03) compared with the
IM-QIV-15 group (GMT 109.3, 95% CI 59.4–200.9).
The GMT in the MAP-FA-2.5 group (participants that received one-sixth the standard dose
of HA) was not significantly different from the GMT in the IM-QIV-15 group at day 4 (GMT
17.4, 95% CI 10.2–29.7 compared with GMT 12.7, 95% CI 7.3–22.3, p = 0.40), day 8 (GMT
72.1, 95% CI 40.4–128.7 compared with GMT 82.8, 95% CI 42.4–161.8, p = 0.74), day 22
(GMT 144.2, 95% CI 77.9–267.0 compared with GMT 139.3, 95% CI 79.3–244.5, p = 0.93), or
day 61 (GMT 125.5, 95% CI 71.0–221.9 compared with GMT 109.3, 95% CI 59.4–200.9, p =
0.73) after vaccination. Furthermore, at day 22 the HAI GMTs were similar in the MAP-FA-15
(GMT 320, 95% CI 161–638) and MAP-UA-15 (GMT 368, 95% CI 198–683) groups, indicat-
ing that the site of HD-MAP application did not appear to affect the subsequent antibody
response.
The HAI GMTs, seroprotection, and seroconversion rates and fold-increase in GMT titres
for all time points are shown in Table 4. All treatment groups that received active vaccine met
the previous Committee for Medicinal Products for Human Use (CHMP) criteria from day 8
onwards [25]. The fold-increases in GMT at day 8 were significantly higher in the MAP-FA-10
(22.6, 95% CI 10.9–47.1, p = 0.007) and MAP-UA-15 groups (18.4, 95% CI 10.3–32.9, p = 0.01)
compared with the IM-QIV-15 group (6.7, 95% CI 4.1–11.1) indicating a more rapid antibody
response compared with IM injection. The fold-changes from baseline remained significantly
higher in the MAP-UA-15 group at days 22 (27.9, 95% CI 15.0–51.7, p = 0.02) and days 61
(21.1, 95% CI 12.0–37.0, p = 0.03) than the IM-QIV-15 group at day 22 (11.3, 95% CI 6.8–
Fig 6. HAI titres for participants in part B at study days 1 (prevaccination), 4, 8, 22, and 61. Participants were
vaccinated with A/Singapore/GP1908/2015 H1N1 at 15, 10, 5, or 2.5 μg HA/dose delivered by HD-MAPs applied to
the volar forearm (MAP-FA-15, MAP-FA-10, MAP-FA-5, MAP-FA-2.5); uncoated HD-MAPs (MAP-FA-0); A/
Singapore/GP1908/2015 H1N1 at 15 μg HA/dose delivered by HD-MAP applied to the upper arm (MAP-UA-15); or
injected IM as a component of the Afluria quadrivalent vaccine (IM-QIV-15). Symbols represent the GMTs and the
error bars show the 95% confidence intervals. GMT, geometric mean titre; HAI, HA inhibition; HD-MAP, high-
density microarray patch; IM, intramuscular.
https://doi.org/10.1371/journal.pmed.1003024.g006
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Table 4. HAI responses to vaccination in terms of seroprotection, seroconversion, and fold-increase in GMT above prevaccination levels for part B.
Day Responses MAP-FA-15 MAP-FA-10 MAP-FA-5 MAP-FA-2.5 MAP-FA-0 MAP-UA-15 IM-QIV-15
Day 1 GMT (95% CI) 20.7 (11.7–36.7) 19.3 (11.0–33.9) 23.0 (12.5–42.3) 16.2 (9.8–26.9) 13.2 (6.7–
26.0)
13.2 (7.7–22.7) 12.3 (7.2–21.1)
Seroprotection; N (%) 10/20 (50) 9/20 (45) 8/20 (40) 8/20 (40) 6/20 (30) 6/20 (30) 7/20 (35)
p = 0.52 p = 0.75 p = 1.00 p = 1.00 p = 1.00
Day 4 GMT (95% CI) 20.7 (11.4–37.7) 18.7 (10.8–32.2) 23.1 (12.3–43.7) 17.4 (10.2–29.7) 13.2 (6.7–
26.0)
14.1 (8.0–25.0) 12.7 (7.3–22.3)
p = 0.22 p = 0.31 p = 0.15 p = 0.40 p = 0.79
Seroprotection; N (%) 10/20 (50) 9/20 (45) 7/19 (37) 8/20 (40) 6/20 (30) 7/20 (35) 7/20 (35)
p = 0.52 p = 0.75 p = 1.00 p = 1.00 p = 1.00
Seroconversion; N (%) 0/20 (0) 0/20 (0) 0/19 (0) 0/20 (0) 0/20 (0) 0/20 (0) 0/20 (0)
N/A N/A N/A N/A N/A
GMT fold-increase (95%
CI)
1.0 (0.9–1.1) 1.0 (0.91.0) 1.0 (1.0–1.1) 1.1 (1.0–1.2) 1.0 (1.0–1.0) 1.1 (1.0–1.2) 1.0 (1.0–1.1)
p = 0.57 p = 0.17 p = 0.97 p = 0.56 p = 0.56
Day 8 GMT (95% CI) 218.6 (111.9–
427.0)
437.1
(254.3751.3)
125.5 (61.4–
256.9)
72.1 (40.4–
128.7)
13.7 (6.8–
27.6)
242.5 (133.2–
441.5)
82.8 (42.4–
161.8)
p = 0.04� p< 0.001�� p = 38 p = 0.74 p = 0.02 �
Seroprotection; N (%) 19/20 (95) 20/20 (100) 17/20 (85) 18/20 (90) 6/20 (30) 18/20 (90) 17/20 (85)
p = 0.60 p = 0.23 p = 1.00 p = 1.00 p = 1.00
Seroconversion; N (%) 17/20 (85) 18/20 (90) 12/20 (60) 11/20 (55) 0/20 (0) 18/20 (90) 15/20 (75)
p = 0.69 p = 0.41 p = 0.50 p = 0.32 p = 0.41
GMT fold-increase (95%
CI)
10.6 (4.8–23.3) 22.6 (10.9–47.1) 5.5 (3.0, 10.0) 4.4 (2.8–7.0) 1.0 (1.0–1.1) 18.4 (10.3–32.9) 6.7 (4.1–11.1)
p = 0.32 p = 0.007�� p = 0.59 p = 0.21 p = 0.001��
Day
22
GMT (95% CI) 320.0 (160.5–
638.1)
485.0 (301.5–
780.2)
234.3 (121.9–
450.0)
144.2 (77.9–
267.0)
13.2 (6.7–
26.0)
367.6 (197.9–
682.7)
139.3 (79.3–
244.5)
p = 0.58 p = 0.001�� p = 0.21 p = 0.93 p = 0.02�
Seroprotection; N (%) 19/20 (95) 20/20 (100) 18/20 (90) 18/20 (90) 6/20 (30) 19/20 (95) 17/20 (85)
p = 0.60 p = 0.23 p = 1.00 p = 1.00 p = 0.60
Seroconversion; N (%) 17/20 (85) 18/20 (90) 14/20 (70) 16/20 (80) 0/20 (0) 18/20 (90) 15/20 (75)
p = 0.69 p = 0.41 p = 1.00 p = 1.00 p = 0.41
GMT fold-increase (95%
CI)
15.5 (6.7–35.7) 25.1 (13.4–46.9) 10.2 (5.1–20.4) 8.9 (5.0–15.8) 1.0 (1.0–1.0) 27.9 (15.0–51.7) 11.3 (6.8–18.8)
p = 0.51 p = 0.05� p = 0.80 p = 0.51 p = 0.02�
Day
61
GMT (95% CI) 211.1 (121.7–
366.3)
309.1 (199.1–
479.9)
211.1 (121.7–
366.3)
125.5 (71.0–
221.9)
12.7 (6.4–
25.5)
278.6 (152.7–
508.1)
109.3 (59.4–
200.9)
p = 0.10 p = 0.001�� p = 0.10 p = 0.73 p = 0.03�
Seroprotection; N (%) 19/20 (95) 20/20 (100) 19/20 (95) 18/20 (90) 6/20 (30) 19/20 (95) 17/20 (85)
p = 0.60 p = 0.23 p = 0.60 p = 1.00 p = 0.60
Seroconversion; N (%) 16/20 (80) 18/20 (90) 14/20 (70) 15/20 (75) 0/20 (0) 18/20 (90) 13/20 (65)
p = 0.48 p = 0.13 p = 1.00 p = 0.73 p = 0.13
GMT fold-increase (95%
CI)
10.2 (5.1–20.5) 16.0 (9.6–26.8) 9.2 (4.9–17.4) 7.7 (4.4–13.6) 1.0 (0.9–1.0) 21.1 (12.0–37.0) 8.9 (5.1–15.4)
p = 0.75 p = 0.11 p = 0.93 p = 0.71 p = 0.03�
Text in bold indicates that the previous Committee for Medicinal Products for Human Use (CHMP) threshold for the criterion has been met.
�p< 0.05
��p< 0.01 compared to the IM-QIV-15 group by Student t test (fold increase and GMTs) and using a Pearson’s chi-square test with continuity correction for
proportion of participants seroconverted or seroprotected.
N/A (not applicable) indicates no participants seroconverted in this group at this time point.
Abbreviations: FA, forearm; GMT, geometric mean titre; HAI, HA inhibition; IM, intramuscular; MAP, microarray patch; QIV, quadrivalent influenza vaccine; UA,
upper arm
https://doi.org/10.1371/journal.pmed.1003024.t004
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18.8), and day 61 (8.9, 95% CI 5.1–15.4). An analysis of the HAI data using nonparametric
methods and presenting median titres, median fold increase and nonparametric CIs is pre-
sented in S1 Table. The P values obtained from the Mann-Witney test (S1 Table) were very
similar to those obtained from the t test.
The HAI titres observed in part A participants (S1 Fig) receiving vaccine delivered by
HD-MAP were not significantly different from those in the corresponding treatment group in
part B at any time point. A-MAP-FA-15 compared with MAP-FA-15 at day 4 (GMT 14.4, 95%
CI 7.0–29.8 compared with GMT 20.7, 95% CI 11.4–37.7, p = 0.42), day 8 (GMT 335.9, 95% CI
134.7–833.8 compared with GMT 218.6, 95% CI 111.9–427, p = 0.42), day 22 (GMT 422.2,
95% CI 191.3–932.2 compared with GMT 320.0 95% CI 160.5–638.1, p = 0.58), and day 61
(GMT 278.6 95% CI 123.9–626.5 compared with GMT 211.1, 95% CI 121.7–366.3, p = 0.54)
suggesting consistency of delivery and antibody induction. The GMTs induced by IM-QIV-15
in parts A and B were also not significantly different at day 4 (A-IM-QIV-15 GMT 27.7, 95%
CI 15.2–50.2 compared with IM-QIV-15 GMT 12.7, 95% CI 7.3–22.3, p = 0.57), day 8
(A-IM-QIV-15 GMT 152.4, 95% CI 79.0–293.4 compared with IM-QIV-15 GMT 82.8, 95% CI
42.4–161.8, p = 0.19), and day 22 (A-IM-QIV-15 GMT 261.7, 95% CI 162.1–425.1 compared
with IM-QIV-15 GMT 139.3, 95% CI 79.3–244.5, p = 0.10) but were higher in part A at day 61
(A-IM-QIV-15 GMT 261.7, 95% CI 166.4–414.1 compared with IM-QIV-15 GMT 109.3, 95%
CI 59.4–200.9, p = 0.03).
MN assays were carried out on serum samples from all part B participants at day 1 (prevac-
cination) and day 22. As with the HAI antibodies, there was an increase in titre from day 1 to
day 22 in all treatment groups that received the vaccine (S2 Fig). The MN titres at day 22 in the
MAP-FA-15 (GMT 11,362, 95% CI 6,492–19,884), MAP-FA-10 (GMT 18,458, 95% CI 11,359–
29,992) and MAP-UA-15 (GMT 13,219, 95% CI 7,096–24,626) groups were significantly
higher than the IM-QIV-15 group (GMT 3,880, 95% CI 1,924–7,824) (p = 0.02, p = 0.001, and
p = 0.01, respectively). As with the HAI results, the MN GMTs at day 22 in the MAP-FA-2.5
(one-sixth dose) (GMT 5,301, 95% CI 2,509–11,196) and IM-QIV-15 (GMT 3,880, 95% CI
1,924–7,824) groups were similar (S2 Fig).
Titres of HA-specific Fc receptor (FcR) -binding antibodies capable of mediating ADCC
were assayed at days 1 and 22. The midpoint titres increased significantly following vaccine
delivery in the MAP-FA-15 (day 22 = 893.6, 95% CI 550.7–1,236, p< 0.001), MAP-UA-15
(day 22 = 1,433, 95% CI 814.3–2,052, p< 0.001) and IM-QIV-15 (day 22 = 576.8, 95% CI
252.9–900.7, p = 0.002) groups but not in the MAP-FA-0 group (day 22 = 118.9, 95% CI
71.62–166.2, p> 0.99; Fig 7A). There was no significant difference between the midpoint titres
at day 22 in these 3 active groups (MAP-FA-15 compared with IM-QIV-15, p> 0.99;
MAP-UA-15 compared with IM-QIV-15, p> 0.99; MAP-FA-15 compared with MAP-UA-15,
p> 0.99) nor was there a difference when the results were expressed as fold-change from base-
line because of the degree of intragroup variation (Fig 7B).
Assessment of salivary IgA responses
Influenza-specific IgA in saliva was assayed by ELISA in samples taken at days 1, 4, 8, and 22
from participants in groups MAP-FA-0, MAP-FA-15, MAP-UA-15, and IM-QIV-15. Statisti-
cal analysis was not performed because of some saliva samples being incomplete and large
sample variation. However, there was an apparent increase in IgA between day 4 and day 8 in
the MAP-FA-15 and MAP-UA-15 groups, with a 1.92- and 1.57-fold increase, respectively, at
day 8 compared with day 1 (S3 Fig). There was no corresponding increase in the MAP-FA-0
(1.01-fold) group, and a 1.22-fold increase in the IM-QIV-15 groups at the same time point.
IgA titres had returned to near-baseline levels at day 22.
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Frequency and specificity of influenza-specific MBCs
A flow cytometry–based assay using fluorescently labelled recombinant HA probes was used
to assess the frequency and specificity of HA-specific B cells following immunisation [26]. Fre-
quencies of memory B cells (MBCs) binding a HA-Michigan probe (antigenically matched to
A/Singapore/GP1908/2015) increased significantly from day 1 to day 22, following immunisa-
tion with either MAP FA-15 (0.641% to 1.262%, p< 0.001), MAP-UA-15 (0.055% to 1.609%,
p< 0.001), or QIV (0.047% to 0.465%, p< 0.001) but not in the MAP-FA-0 placebo group
(0.051% to 0.131%, p> 0.99). The frequencies of HA-Michigan-specific MBCs at day 22 were
not significantly different in the 3 vaccine groups however (MAP-FA-15 compared with
IM-QIV-15, p> 0.99; MAP-UA-15 compared with IM-QIV-15, p> 0.99; MAP-FA-15 com-
pared with MAP-UA-15, p> 0.99; Fig 8A and Fig 8B). Using binding to a A/New Caledonia/
99 probe to assess H1N1 cross-reactivity, we found only a small proportion of the A/Michi-
gan/15-binding cells displayed cross-reactive recognition of A/New Caledonia/99 HA. There
were significant increases in frequency in these cells between day 1 and day 22 in the MAP-
FA-15 (0.005% to 0.048%, p< 0.001) and MAP-UA-15 (0.002% to 0.047%, p< 0.001) groups,
and an increase that did not reach statistical significance in the IM-QIV-15 groups (0.004% to
0.026%, p = 0.05), but again, there were no differences in the MBC frequency in the vaccine
groups at day 22 (MAP-FA-15 compared with IM-QIV-15, p> 0.99; MAP-UA-15 compared
with IM-QIV-15, p> 0.99; MAP-FA-15 compared with MAP-UA-15, p> 0.99; Fig 8C and
Fig 8D). A similar pattern was seen with cross-reactive B cells binding an HA-stalk domain
probe; there was a significant expansion from day 1 to day 22 in the MAP FA-15 (0.126% to
0.507%, p = 0.01) and IM-QIV-15 (0.128% to 0.368%, p = 0.05) groups. The expansion in the
MAP-UA-15 groups did not achieve significance, probably because of intragroup variability
(0.128% to 0.569%, p = 0.17). There was no difference in stalk-reactive MBC frequencies
between the active HD-MAP and IM groups at day 22 (MAP-FA-15 compared with IM-QIV-
15, p> 0.99; MAP-UA-15 compared with IM-QIV-15, p> 0.99; MAP-FA-15 compared with
MAP-UA-15, p> 0.99; Fig 8E and Fig 8F).
Flow-cytometric analysis of influenza-specific polyfunctional T cells
T-cell responses were assessed by analysing the frequencies of influenza-specific CD4+ and
CD8+ T producing IFN-γ, IL-2, and TNF-α in PBMC harvested on days 1 and 22 from
Fig 7. HA-specific FcR-binding antibodies. Antibodies specific for A/Singapore/GP1908/2015 monovalent purified
harvest that engage with dimeric, soluble recombinant FcγRIII were measured by ELISA. (A) Midpoint ELISA titres.
(B) Fold-change in midpoint titres, day 22 versus day 1. Symbols represent individual responses before (D1) and after
(D22) immunisation, in which horizontal lines indicate the mean response (A); columns with error bars represent the
median with interquartile ranges (B). ELISA, enzyme-linked immunosorbent assay; FcR, Fc receptor; HA,
haemagglutinin.
https://doi.org/10.1371/journal.pmed.1003024.g007
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Fig 8. MBC frequencies pre- and postvaccination. The frequencies of HA-specific MBC were assessed in cryopreserved PBMC samples by flow
cytometry. Samples were gated for live, CD19+, IgD negative B cells, and specificity determined based upon binding to A/Michigan/2015 probes
A phase I clinical trial evaluating influenza vaccination using a HD-MAP
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participants in groups MAP-FA-0, MAP-FA-15, MAP-UA-15, and IM-QIV-15. PBMC were
stimulated with either A/Sing MPH or overlapping peptides spanning the A/Sing HA
sequence.
There was an increase in the overall frequency of CD4+ cells producing IFN-γ, IL-2, or
TNF-α following in vitro stimulation with the peptides at day 22 compared to day 1 in the
MAP-FA-15, MAP-UA-15, and IM-QIV-15 groups but not the MAP-FA-0 group (Fig 9A). In
particular, there was a significant increase in the abundance of polyfunctional CD4+ T cells
expressing all 3 cytokines (IFN-γ, TNF-α, and IL-2) at day 22 compared with day 1 for the
MAP-FA-15 (0.006% to 0.022%, p< 0.001, 95% CI −0.00011 to 0.0002), MAP-UA-15 (0.009%
to 0.018%, p = 0.005, 95% CI −0.00007 to 0.0002), and IM-QIV-15 (0.007% to 0.016%, p =
0.01, 95% CI −0.00011 to 0.00025) groups. There were no statistically significant differences in
the proportions of CD4+ T cells producing any of the cytokine combinations at day 22 when
the MAP-FA-15, MAP-UA-15, and IM-QIV-15 groups were compared with one another.
The overall frequency of cytokine-producing CD4+ cells pre- and postvaccination was
greater following stimulation with A/Sing MPH compared with the overlapping peptides (Fig
9B), presumably because of the greater number of epitopes present within the MPH prepara-
tion. A/Sing MPH stimulation appeared to induce more CD4+ cells producing TNF-α alone
compared with peptide stimulation. There were not, however, any statistically significant dif-
ferences in the proportions of CD4+ T cells producing each of the cytokine combinations at
day 22 when the MAP-FA-15, MAP-UA-15, and IM-QIV-15 groups were compared with one
another (p> 0.05 for all comparisons).
Day 1 and day 22 CD8+ T-cell responses to the peptide pools and A/Sing MPH were also
measured but were weak in comparison with the CD4+ responses. The weak CD8+ T-cell
responses were not surprising considering that the nature of antigen used for restimulation
(inactivated, split A/Sing MPH, and 17 amino acid peptides) favoured stimulation and detec-
tion of CD4+ T cells
Discussion
This phase I clinical trial demonstrated that HD-MAPs delivering a monovalent influenza vac-
cine were well tolerated and induced immune responses that were similar to or significantly
enhanced compared with IM injection. The study was the first clinical trial with Vaxxas
HD-MAPs fabricated from polymer, rather than silicon Nanopatches, as used in our previous
studies [2,19]. In addition, the trial reported here was, to our knowledge, the first clinical study
with any MAP to evaluate the potential for dose-sparing, a phenomenon that has been tested
extensively in preclinical models [10–17] but, until now, has not been demonstrated in the
clinic.
The HD-MAPs were found to be safe and well tolerated, and the safety and reactogenicity
profiles of the HD-MAPs were very similar to those observed with the silicon Nanopatches
using a similar H1N1 antigen, A/California/7/2009 [2,19]. The observation that erythema was
still present 7 days after vaccination is also consistent with intradermal (ID) delivery of influ-
enza vaccines [27]. The acceptability of the HD-MAP was not assessed in this study, but our
previous studies found that the majority of participants preferred the Nanopatch to IM
alone or in combination with A/New Caledonia/1999 or a stabilised H1N1 stem probes. (A and B) A/Michigan/2015 H1N1; (C and D) A/New
Caledonia/1999 and A/Michigan/2015 H1N1 cross-reactive MBC; (E and F) H1 stem. Results are expressed as the frequency of probe-binding cells
at days 1 and 22 (A, C, and E) with symbols representing individual responses before (D1) and after (D22) immunisation, and horizontal lines
indicating the mean response; fold-change at day 22 compared with baseline (B, D, and F). Columns represent the median fold change; error bars
represent the median with interquartile ranges. HA, haemagglutinin; MBC, memory B cell; PBMC, peripheral blood mononuclear cell.
https://doi.org/10.1371/journal.pmed.1003024.g008
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injection with N&S [2,19], and similar results have also been obtained with other MAP systems
[7,28].
Assessment of the immune response was a secondary objective in the study. In terms of the
proportion of participants seroprotected and seroconverting, the HAI responses induced by
HD-MAP delivery in this study were similar to those seen previously with N&S ID injection of
inactivated influenza vaccine (IIVs) [27,29–33]. However, the more rapid antibody response
seen with HD-MAP delivery as indicated by higher HAI titres at the early day 8 time point
have not, to the best of our knowledge, been seen with ID injection of IIVs unless the ID injec-
tion site was pretreated with the topical adjuvant Imiquimod, a toll-like receptor 7 agonist
[34]. Achieving higher titres sooner after vaccination by using the HD-MAP to deliver seasonal
influenza or travel vaccines would be beneficial for vaccine recipients and would be particu-
larly valuable if it was shown to apply to vaccines against pandemic influenza strains and vac-
cines used in outbreak response.
We conducted several exploratory assays to define whether differences exist in the immune
response induced by HD-MAP delivery compared with IM injection. These assays were only
conducted on samples from participants in the groups that received the 15 μg or 0 μg doses of
HA, so no data were collected on whether or not similar responses would have been seen in
these assays with the lower doses of the HD-MAP-delivered vaccine. Overall, HD-MAP deliv-
ery of inactivated split influenza vaccine gave comparable albeit increased levels of response in
all immunological parameters tested, indicating a broad engagement of the immune system by
the Vaxxas HD-MAP.
Influenza vaccines that induce more broadly protective and longer lasting immunity than
current seasonal vaccines are needed to limit the consequences of epidemic and pandemic
influenza [35,36]. Studies have suggested that ADCC-mediating antibodies recognize epitopes
that are more conserved than those bound by neutralising antibodies and might contribute to
protection against heterologous strains [37,38]. In our study, the induction of antibodies with
ADCC-inducing potential followed a similar pattern of response to the HAI and MN data,
with slightly higher titres being observed in groups vaccinated with the HD-MAP compared
with the IM injection. The frequencies of B cells recognizing HA-stalk and a historic H1N1
HA probes also increased to a similar extent following IM or HD-MAP vaccination.
CD4+ T-cell responses to influenza can have broad specificity and contribute to protection
by several mechanisms including providing help for high-affinity neutralising antibody
responses; recruiting effector cells; directly lysing infected cells and producing antiviral cyto-
kines such as IFN-γ, and providing long-lived, cross-reactive memory [39]. Our observation
that the frequency of CD4+ cells responding to the HA peptide pools in participants vaccinated
by HD-MAP was at least as high as that in participants vaccinated IM is consistent with the
overall pattern of responses to HD-MAP vaccination being as good or enhanced compared
with IM injection.
Induction of mucosal immune responses by influenza vaccines would be advantageous,
because these responses could control or limit virus replication in the respiratory tract [40]. ID
or MAP immunisation has been shown to induce mucosal responses to nonlive vaccines
including influenza in mice and swine [17,41–43]. In humans, however, ID delivery of IIVs
Fig 9. Frequency of CD4+ cells producing IL-2, TNF-α, or IFN-γ following stimulation of PBMC with (A) overlapping peptides
spanning A/Sing HA (5 μg/ml) or (B) A/Sing MPH (20 μg/ml). Cells were labelled with Live/Dead Aqua for viability; CD3, CD4, and
CD8; permeabilised; and subsequently labelled with anti-IFN-γ, anti-TNF-α, and anti-IL-2. Approximately 500,000 events were acquired
using a Becton Dickinson LSR Fortessa X20 and data analysed using SPICE software. Day 1 versus day 22 comparisons were made using the
Wilcoxon rank sum test: ��p< 0.01, �p< 0.05. HA, haemagglutinin; IFN, interferon; IL, interleukinMPH, monovalent purified harvest;
PBMC, peripheral blood mononuclear cell; TNF, tumour necrosis factor.
https://doi.org/10.1371/journal.pmed.1003024.g009
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did not induce superior IgA responses compared with IM [44]. In contrast, superior IgA
responses were induced in a phase I trial of trans-cutaneous delivery of live-attenuated measles
vaccine [45]. We observed a small increase in salivary IgA on day 8 following HD-MAP deliv-
ery of the A/Sing antigen but not following IM injection of QIV. Given the method of collec-
tion, however, we cannot rule out the possibility that the saliva was contaminated with
crevicular fluid, and as such, might reflect responses in the serum, rather than mucosal
responses.
In contrast to our previous study using silicon Nanopatches [2], in which application to the
forearm appeared to be marginally more immunogenic, no differences in the HAI or MN
responses were found following HD-MAP application to the UA or volar surface of the fore-
arm, suggesting that either application site could be used in the future.
The small group sizes limited the statistical power of the study. However, even with these
numbers, several Vaxxas HD-MAP groups showed statistically higher responses at days 8, 22,
and 61 after vaccination compared with IM injection, and the one-sixth dose induced antibody
levels that were similar to those seen with the full-dose IM. At this stage, we do not understand
the influence of prior immunity to H1N1 on immunological responses. This will be further
investigated by a larger trial that will include H3 and B strains delivered by the HD-MAP.
Lower doses than 2.5 μg were not tested in the study and, a further reduction in delivered HA
dose may be achievable: in preclinical studies, 1/100th or 10th doses of flu vaccine delivered by
Nanopatch induced a similar antibody response to IM and ID injection, respectively [10].
However, the development of Intanza 9 μg, ID seasonal influenza vaccine found that higher
doses were required to achieve noninferiority, compared to responses seen in early clinical
studies [46]. Full analysis of the dose-sparing potential of HD-MAPs with influenza vaccines
would involve clinical testing of all reduced dose levels of the same antigen delivered by IM
and HD-MAP, but such a large study was beyond the scope of this phase I study that was the
first clinical use of the Vaxxas polymer HD-MAP. Finally, the fact that local skin reactions to
uncoated or vaccine-coated HD-MAPs were different could have compromised the blinding
of the study. However, all laboratory staff were completely blinded to this information
throughout the trial.
The Vaxxas HD-MAP product under test here was a developmental version of the intended
commercial product and as such has more components and a more complex administration
process. However, all the parameters associated with the actual application of the HD-MAP
(such as contact points with the skin, the force generated by the applicator, size of the MAP,
etc.) were the same in this device as in the proposed final commercial product. The final prod-
uct design is an integrated single use, autodisabling, and disposable applicator, and this will be
used in the next clinical study. This design will reduce the overall system cost of the product
for which, in the influenza market at least, needs to be competitive to a prefilled N&S. A proto-
type version of the commercial device has been evaluated in an end-user study conducted in
Benin, Nepal, and Vietnam and was found to be very acceptable to immunisation managers,
healthcare workers, community health volunteers, and caregivers [47]. The demonstration in
this study that Vaxxas HD-MAPs fabricated from polymer rather than silicon can be manufac-
tured and used for vaccine delivery is a significant advance. Polymer is preferred to silicon for
the final commercial embodiment of the device because HD-MAPs will be significantly less
expensive per unit than silicon Nanopatches and will be more amenable to large-scale manu-
facture—a major challenge for all MAP developers. Finally, future versions of the device and
future trials will evaluate delivery of the standard dose (15 μg HA per strain) by a single
HD-MAP.
Influenza causes significant morbidity and mortality in adults over 65 years of age, and
strategies to improve vaccine coverage, immunogenicity, and effectiveness in this age group
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are required [48]. Currently IIVs for this population require chemical adjuvants such as MF59
or high doses of antigen (such as 60 μg HA per strain per dose present in HD Fluzone) to
achieve satisfactory immune responses [48,49]. The enhanced immunogenicity seen with
MAP delivery indicates that HD-MAPs may provide an alternative approach; however,
whether any differences seen in the immune responses induced by HD-MAPs compared with
IM injection are clinically relevant will require large-scale studies with clinical endpoints.
Furthermore, the exceptional thermostability of the influenza vaccine observed in this
study compared with standard formulations [50] would eliminate dependence on the cold-
chain and reduce vaccine wastage due to cold-chain excursions. A more stable vaccine would
also remove the need to overload the patch to compensate for loss of potency during the shelf
life of the vaccine.
If the dose-sparing observed with an H1N1 strain in this trial is also observed with other
influenza strains, use of the Vaxxas HD-MAP could increase the number of vaccine doses that
can be produced from the primary manufacturing facility in a season, or in a pandemic,
because the amount of antigen required per dose would be reduced. Global capacity for sea-
sonal influenza production declined between 2013 and 2015, largely because of the switch
from TIV to QIV formulations [51], and pandemic vaccine production capacity is dependent
on the implementation of dose-sparing strategies [51]. Dose-sparing and rapid onset of protec-
tive immunity would also be a very valuable attribute for many other vaccines of global health
importance such as inactivated poliovirus vaccine or yellow fever vaccine for which use is lim-
ited by chronic supply constraints [52–54], or by cost, such as rabies vaccine [55]. These vac-
cines are often needed most in low-resource settings where other key attributes of the Vaxxas
HD-MAP, such as thermostability, ease of use, acceptability, and the avoidance of reconstitu-
tion would also be very beneficial [47].
In summary, this was the first clinical trial using Vaxxas HD-MAPs fabricated from poly-
mer, coated with an influenza vaccine. The HD-MAP appeared to be safe and well tolerated.
Doses of 2.5, 5, 10, and 15 μg HA induced HAI and MN responses as high or higher than 15 μg
HA injected IM. This is to the best of our knowledge the first clinical demonstration of dose-
sparing for vaccine delivery using a MAP technology. Future clinical studies will evaluate the
acceptability and immunogenicity of QIVs delivered by Vaxxas HD-MAP in adults and older
adults and examine the immunogenicity of vaccines against potential pandemic strains of
influenza. Clinical trials using Vaxxas HD-MAPs are also warranted to determine whether the
dose-sparing seen in this trial is seen with other types of vaccines.
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S1 Fig. HAI titres for part A. HAI titres at days 1 (prevaccination), 4, 8, 22, and 61 for partici-
pants in part A following vaccination with either A/Singapore/GP1908/2015 H1N1 delivered
by HD-MAP (A-MAP-FA-15) or injected IM as a component of Afluria quadrivalent vaccine
(A-IM-QIV-15), uncoated HD-MAP (A-MAP-FA-0), or A/Singapore/GP1908/2015 H1N1
monovalent pooled harvest injected IM (IM-SIN-15). Symbols represent the GMTs and error
bars show the 95% confidence intervals. The dotted line indicates the HAI titre (1:40) regarded
as correlating with protection. FA, forearm; GMT, geometric mean titre; HAI, HA inhibition;
HD-MAP, high-density microarray patch; IM, intramuscular; QIV, quadrivalent influenza
vaccine
(TIF)
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S2 Fig. Microneutralisation titres, part B. Microneutralisation titres at day 1 (prevaccination)
and day 22 for participants in part B following vaccination with A/Singapore/GP1908/2015
H1N1 at 15, 10, 5, or 2.5 μg HA/dose delivered by HD-MAPs applied to the volar forearm
(MAP-FA-15, MAP-FA-10, MAP-FA-5, MAP-FA-2.5), uncoated HD-MAPs (MAP-FA-0), A/
Singapore/GP1908/2015 H1N1 at 15 μg HA/dose delivered by HD-MAP applied to the upper
arm (MAP-UA-15), or injected IM as a component of Afluria quadrivalent vaccine (IM-QIV-
15). Columns represent the GMTs, symbols represent the titres from individual participants,
and the error bars show the 95% confidence intervals. FA, forearm; GMT, geometric mean
titre; HA, haemagglutinin; HD-MAP, high-density microarray patch; IM, intramuscular; QIV,
quadrivalent influenza vaccine; UA, upper arm
(TIF)
S3 Fig. Influenza-specific IgA titres in saliva samples. Participants were vaccinated with
either 15 μg of A/Singapore/GP1908/2015 H1N1 delivered by HD-MAP to either the volar
forearm (MAP-FA-15) or upper arm (MAP-UA-15), or injected IM as a component of Afluria
quadrivalent vaccine (IM-QIV-15) or uncoated HD-MAPs (MAP-FA-0). Four time points
were measured: prevaccination (day 1), day 4, 8, and 22. The absorbance values per group for
each time point were averaged and compared against day 1, and the fold-change compared
with prevaccination (day 1) were plotted. Symbols represent the means from all participants
per group, and the error bars show the 95% confidence intervals. Statistical analysis was not
performed because of some saliva samples being incomplete and large sample variation. FA,
forearm; HD-MAP, high-density microarray patch; IgA, immunoglobulin A; IM, intramuscu-
lar; QIV, quadrivalent influenza vaccine; UA, upper arm
(TIF)
S1 Table. HAI responses, part B, nonparametric analysis. HAI responses to vaccination in
terms of median titre, seroprotection, seroconversion, and fold-increase in median titre above
prevaccination levels for part B. Part B participants were vaccinated with A/Singapore/
GP1908/2015 H1N1 at 15, 10, 5, or 2.5 μg HA/dose delivered by HD-MAPs applied to the
volar forearm (MAP-FA-15, MAP-FA-10, MAP-FA-5, MAP-FA-2.5), uncoated HD-MAPs
(MAP-FA-0), A/Singapore/GP1908/2015 H1N1 at 15 μg HA/dose delivered by HD-MAP
applied to the upper arm (MAP-UA-15), or injected IM as a component of the Afluria quadri-
valent vaccine (IM-QIV-15). Exact nonparametric CIs are shown in parentheses. �p< 0.05;
��p< 0.01 compared to the IM-QIV-15 group by Exact Mann Witney Test (median titre and
median fold increase). Pearson’s chi-square test with continuity correction was used to com-
pare proportion of participants seroconverted or seroprotected. FA, forearm; HA, haemagglu-
tinin; HAI, HA inhibition; HD-MAP, high-density microarray patch; IM, intramuscular; QIV,
quadrivalent influenza vaccine; UA, upper arm.
(DOCX)
S2 Table. Microneutralisation responses, part B, nonparametric analysis. Microneutralisa-
tion responses (median titres) at days 1 and 22 for part B. Part B participants were vaccinated
with A/Singapore/GP1908/2015 H1N1 at 15, 10, 5, or 2.5 μg HA/dose delivered by HD-MAPs
applied to the volar forearm (MAP-FA-15, MAP-FA-10, MAP-FA-5, MAP-FA-2.5), uncoated
HD-MAPs (MAP-FA-0), A/Singapore/GP1908/2015 H1N1 at 15 μg HA/dose delivered by
HD-MAP applied to the upper arm (MAP-UA-15), or injected IM as a component of the
Afluria quadrivalent vaccine (IM-QIV-15). Exact nonparametric CIs are shown in parenthe-
ses. �p< 0.05; ��p< 0.01 compared to the IM-QIV-15 group by Exact Mann Witney Test. FA,
forearm; HA, haemagglutinin; HD-MAP, high-density microarray patch; IM, intramuscular;
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QIV, quadrivalent influenza vaccine; UA, upper arm
(DOCX)
S1 Text. Clinical trial protocol.
(PDF)
S1 Data. Data listing. Data 1: Informed Consent; Data 2: Analysis Sets; Data 3: Demographics;
Data 4: Study Drug Administration; Data 5: Skin Hardness Assessment; Data 6: Immunoge-
nicity (ELISA IgG); Data 7: Immunogenicity (ADCC); Data 8: Immunogenicity (MBCs); Data
9: Immunogenicity (CMI); Data 10: Immunogenicity (Mucosal IgA); Data 11: Immunogenic-
ity Results (HAI, MN); Data 12: TEAE–CRF Data only; Data 13: TEAEs–MedDRA Coding;
Data 15: Treatment Site Tolerability Assessment; Data 16: Numeric Pain Intensity; Data 17:
SII; Data 18: Application Site Status at End of Study; Data 19: Individual Treatment Site Toler-
ability Assessment; Data 20: Numeric Pain Intensity by Treatment; Data 21: Individual SII by
Treatment. ADCC, antibody-dependent cellular cytotoxicity; CMI, cell-mediated immunity;
CRF, case report form; ELISA, enzyme-linked immunosorbent assay; HAI, haemagglutination
inhibition; IgA, immunoglobulin A; IgG, immunoglobulin G; MBC, memory B cell; MedDRA,
medical dictionary for regulatory activities; MN, microneutralisation; SII, Skin Irritation
Index; TEA, treatment emergent adverse event.
(ZIP)
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